441 related articles for article (PubMed ID: 28948533)
1. Remyelinating Pharmacotherapies in Multiple Sclerosis.
Bove RM; Green AJ
Neurotherapeutics; 2017 Oct; 14(4):894-904. PubMed ID: 28948533
[TBL] [Abstract][Full Text] [Related]
2. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
Keirstead HS; Blakemore WF
Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
[TBL] [Abstract][Full Text] [Related]
3. Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches.
Olsen JA; Akirav EM
J Neurosci Res; 2015 May; 93(5):687-96. PubMed ID: 25287108
[TBL] [Abstract][Full Text] [Related]
4. Remyelinating strategies: What can be learned from normal brain development.
Shelestak J; Irfan M; DeSilva TM
Curr Opin Pharmacol; 2022 Dec; 67():102290. PubMed ID: 36195009
[TBL] [Abstract][Full Text] [Related]
5. Development of a central nervous system axonal myelination assay for high throughput screening.
Lariosa-Willingham KD; Rosler ES; Tung JS; Dugas JC; Collins TL; Leonoudakis D
BMC Neurosci; 2016 Apr; 17():16. PubMed ID: 27103572
[TBL] [Abstract][Full Text] [Related]
6. Remyelinating strategies in multiple sclerosis.
Luessi F; Kuhlmann T; Zipp F
Expert Rev Neurother; 2014 Nov; 14(11):1315-34. PubMed ID: 25331418
[TBL] [Abstract][Full Text] [Related]
7. Promoting remyelination in multiple sclerosis: current drugs and future prospects.
Kremer D; Küry P; Dutta R
Mult Scler; 2015 Apr; 21(5):541-9. PubMed ID: 25623245
[TBL] [Abstract][Full Text] [Related]
8. The Study of Remyelinating Therapies in Multiple Sclerosis: Visual Outcomes as a Window Into Repair.
Zuroff LR; Green AJ
J Neuroophthalmol; 2024 Jun; 44(2):143-156. PubMed ID: 38654413
[TBL] [Abstract][Full Text] [Related]
9. Inflammation stimulates remyelination in areas of chronic demyelination.
Foote AK; Blakemore WF
Brain; 2005 Mar; 128(Pt 3):528-39. PubMed ID: 15699059
[TBL] [Abstract][Full Text] [Related]
10. Oligodendrocyte progenitor cell recruitment and remyelination in multiple sclerosis: the more, the merrier?
Tepavčević V; Lubetzki C
Brain; 2022 Dec; 145(12):4178-4192. PubMed ID: 36093726
[TBL] [Abstract][Full Text] [Related]
11. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials.
Sutiwisesak R; Burns TC; Rodriguez M; Warrington AE
Expert Opin Investig Drugs; 2021 Aug; 30(8):857-876. PubMed ID: 34126015
[No Abstract] [Full Text] [Related]
12. Attempts to Overcome Remyelination Failure: Toward Opening New Therapeutic Avenues for Multiple Sclerosis.
Motavaf M; Sadeghizadeh M; Javan M
Cell Mol Neurobiol; 2017 Nov; 37(8):1335-1348. PubMed ID: 28224237
[TBL] [Abstract][Full Text] [Related]
13. Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
Pan S; Chan JR
Ann Neurol; 2021 Oct; 90(4):558-567. PubMed ID: 34402546
[TBL] [Abstract][Full Text] [Related]
14. Myelin repair stimulated by CNS-selective thyroid hormone action.
Hartley MD; Banerji T; Tagge IJ; Kirkemo LL; Chaudhary P; Calkins E; Galipeau D; Shokat MD; DeBell MJ; Van Leuven S; Miller H; Marracci G; Pocius E; Banerji T; Ferrara SJ; Meinig JM; Emery B; Bourdette D; Scanlan TS
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996143
[TBL] [Abstract][Full Text] [Related]
15. Remyelination in multiple sclerosis.
Chari DM
Int Rev Neurobiol; 2007; 79():589-620. PubMed ID: 17531860
[TBL] [Abstract][Full Text] [Related]
16. Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy.
Cordano C; Sin JH; Timmons G; Yiu HH; Stebbins K; Guglielmetti C; Cruz-Herranz A; Xin W; Lorrain D; Chan JR; Green AJ
Brain; 2022 Nov; 145(11):3943-3952. PubMed ID: 35678509
[TBL] [Abstract][Full Text] [Related]
17. To what extent is oligodendrocyte progenitor migration a limiting factor in the remyelination of multiple sclerosis lesions?
Franklin RJ; Blakemore WF
Mult Scler; 1997 Apr; 3(2):84-7. PubMed ID: 9291159
[TBL] [Abstract][Full Text] [Related]
18. The Current Challenges for Drug Discovery in CNS Remyelination.
Balestri S; Del Giovane A; Sposato C; Ferrarelli M; Ragnini-Wilson A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809224
[TBL] [Abstract][Full Text] [Related]
19. Do central nervous system axons remyelinate?
Nait-Oumesmar B; Lachapelle F; Decker L; Baron-Van Evercooren A
Pathol Biol (Paris); 2000 Feb; 48(1):70-9. PubMed ID: 10729914
[TBL] [Abstract][Full Text] [Related]
20. Artificial axons as a biomimetic 3D myelination platform for the discovery and validation of promyelinating compounds.
Jagielska A; Radzwill K; Espinosa-Hoyos D; Yang M; Kowsari K; Farley JE; Giera S; Byrne A; Sheng G; Fang NX; Dodge JC; Pedraza CE; Van Vliet KJ
Sci Rep; 2023 Nov; 13(1):19529. PubMed ID: 37945646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
